Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
94.14(c) 95.1(c) 94.55(c) 94.3(c) 93.76 Last
14 038 236 7 268 628 8 169 284 7 646 835 10 264 860 Volume
-0.10% +1.02% -0.58% -0.26% -0.57% Change
More quotes
Financials (USD)
Sales 2019 17 113 M
EBIT 2019 9 837 M
Net income 2019 6 141 M
Debt 2019 7 342 M
Yield 2019 -
Sales 2020 19 280 M
EBIT 2020 11 327 M
Net income 2020 7 485 M
Debt 2020 2 255 M
Yield 2020 -
P/E ratio 2019 10,82
P/E ratio 2020 8,96
EV / Sales2019 4,30x
EV / Sales2020 3,55x
Capitalization 66 241 M
More Financials
Company
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.8%); - other (0.2%): cellular therapy products and biological materials for implants, for... 
Sector
Pharmaceuticals
Calendar
05/05Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
04/16CELGENE : Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
AQ
04/15BRISTOL MYERS SQUIBB : Shareholders Approve Celgene Acquisition
AQ
04/15CELGENE : Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
AQ
04/15BRISTOL MYERS SQUIBB : Celgene Deal Clears A Hurdle
DJ
04/12CELGENE CORP /DE/ : Submission of Matters to a Vote of Security Holders, Other E..
AQ
04/12BRISTOL MYERS SQUIBB : Myers says shareholders vote to approve Celgene takeover
RE
04/12BRISTOL MYERS SQUIBB : Myers Shareholders Approve $74 Billion Deal For Celgene -..
DJ
04/12BRISTOL MYERS SQUIBB : Myers Shareholders Approve $74 Billion Deal For Celgene
DJ
04/12BRISTOL MYERS SQUIBB : Myers Shareholders Vote in Favor of $74 Billion Celgene A..
DJ
04/12CELGENE : Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
BU
More news
Analyst Recommendations on CELGENE CORPORATION
More recommendations
Stock Trading Strategies
CELGENE CORPORATION - 03/28
In an accumulation phase
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
04/17ACREAGE : Canopy Growth nearing deal to buy U.S.-based pot company Acreage Holdi..
RE
04/17MERCK AND : on Pace for Largest Percent Decrease in Over a Year -- Data Talk
DJ
04/17Roche Raises 2019 Sales View After 1Q Sales Beat
DJ
04/17SPARK THERAPEUTICS : Swiss drugmaker Roche ups outlook as sales growth offsets p..
RE
04/17SPARK THERAPEUTICS : Swiss drugmaker Roche ups outlook as sales growth offsets p..
RE
More sector news : Pharmaceuticals - NEC
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 96,8 $
Spread / Average Target 2,7%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION47.14%66 241
JOHNSON & JOHNSON6.95%368 847
ROCHE HOLDING LTD.9.41%227 539
PFIZER-6.25%221 406
NOVARTIS5.99%199 282
MERCK AND COMPANY-3.26%190 941